13. Goodwill
(thousands of €) |
Goodwill |
|---|---|
On January 1, 2024 |
69,557 |
Exchange differences on goodwill |
453 |
On December 31, 2024 |
70,010 |
Impairment on goodwill |
(69,404) |
Exchange differences on goodwill |
(606) |
On December 31, 2025 |
– |
The goodwill resulting from both the acquisition of CellPoint (€62.4 million) and AboundBio (€7.6 million) at December 31, 2024, was allocated to the same cash-generating unit (CGU), “CAR-T/Cell Therapy”. The intangible assets acquired as a result of both business combinations were also allocated to this cash-generating unit, together with some other (in)tangible assets related to the “CAR-T/Cell Therapy” cash-generating unit. The valuation method of the recoverable amount of this cash-generating unit was based on the fair value less costs of disposal.
As a consequence of the announced wind-down of our cell therapy activities, we fully impaired the associated goodwill. We refer to note 2 for more information about the wind-down of the cell therapy activities and to note 8 for more information about the total impairment loss of the cell therapy activities, included in the consolidated income statement as a separate line item.